These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 29053133)

  • 21. Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinson's Disease.
    Khakimova GR; Kozina EA; Kucheryanu VG; Ugrumov MV
    Mol Neurobiol; 2017 Jul; 54(5):3618-3632. PubMed ID: 27194433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Harnessing neurogenesis for the possible treatment of Parkinson's disease.
    Lamm O; Ganz J; Melamed E; Offen D
    J Comp Neurol; 2014 Aug; 522(12):2817-30. PubMed ID: 24723264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?
    Ling H; Kearney S; Yip HL; Silveira-Moriyama L; Revesz T; Holton JL; Strand C; Davey K; Mok KY; Polke JM; Lees AJ
    J Neurol Neurosurg Psychiatry; 2016 Jun; 87(6):633-41. PubMed ID: 26209716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?
    Herrera A; Muñoz P; Steinbusch HWM; Segura-Aguilar J
    ACS Chem Neurosci; 2017 Apr; 8(4):702-711. PubMed ID: 28233992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease.
    Duda J; Pötschke C; Liss B
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):156-178. PubMed ID: 26865375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of a presymptomatic stage in a Drosophila Parkinson's disease model: Unveiling dopaminergic compensatory mechanisms.
    Molina-Mateo D; Fuenzalida-Uribe N; Hidalgo S; Molina-Fernández C; Abarca J; Zárate RV; Escandón M; Figueroa R; Tevy MF; Campusano JM
    Biochim Biophys Acta Mol Basis Dis; 2017 Nov; 1863(11):2882-2890. PubMed ID: 28716706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation and Analysis of Viral Vector-Mediated Rodent Models for Parkinson's Disease.
    Karikari AA; Koprich JB; Ip CW
    Methods Mol Biol; 2019; 1948():271-286. PubMed ID: 30771185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Wnt/β-catenin signaling plays an essential role in α7 nicotinic receptor-mediated neuroprotection of dopaminergic neurons in a mouse Parkinson's disease model.
    Liu Y; Hao S; Yang B; Fan Y; Qin X; Chen Y; Hu J
    Biochem Pharmacol; 2017 Sep; 140():115-123. PubMed ID: 28551099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Down-regulation of ghrelin receptors on dopaminergic neurons in the substantia nigra contributes to Parkinson's disease-like motor dysfunction.
    Suda Y; Kuzumaki N; Sone T; Narita M; Tanaka K; Hamada Y; Iwasawa C; Shibasaki M; Maekawa A; Matsuo M; Akamatsu W; Hattori N; Okano H; Narita M
    Mol Brain; 2018 Feb; 11(1):6. PubMed ID: 29458391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 6-hydroxydopamine-induced Parkinson's disease-like degeneration generates acute microgliosis and astrogliosis in the nigrostriatal system but no bioluminescence imaging-detectable alteration in adult neurogenesis.
    Fricke IB; Viel T; Worlitzer MM; Collmann FM; Vrachimis A; Faust A; Wachsmuth L; Faber C; Dollé F; Kuhlmann MT; Schäfers K; Hermann S; Schwamborn JC; Jacobs AH
    Eur J Neurosci; 2016 May; 43(10):1352-65. PubMed ID: 26950181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective A
    Fathalla AM; Soliman AM; Moustafa AA
    Neurosci Lett; 2017 Mar; 643():89-96. PubMed ID: 28213070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Female mice are resilient to age-related decline of substantia nigra dopamine neuron firing parameters.
    Howell RD; Dominguez-Lopez S; Ocañas SR; Freeman WM; Beckstead MJ
    Neurobiol Aging; 2020 Nov; 95():195-204. PubMed ID: 32846275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Parkinson's disease: pathogenesis, aetiology, symptoms, diagnostics, and its course].
    de Baat C; van Stiphout MAE; Lobbezoo F; van Dijk KD; Berendse HW
    Ned Tijdschr Tandheelkd; 2018 Oct; 125(10):509-515. PubMed ID: 30317371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuronal vulnerability in Parkinson's disease.
    Hirsch EC; Faucheux B; Damier P; Mouatt-Prigent A; Agid Y
    J Neural Transm Suppl; 1997; 50():79-88. PubMed ID: 9120427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The importance of choosing a preclinical model that reflects what happens in Parkinson's disease.
    Segura-Aguilar J
    Neurochem Int; 2019 Jun; 126():203-209. PubMed ID: 30922924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Commentary: olfactory dysfunction in Parkinson's disease.
    Li J; Cui Y; Yuan TF; Arias-Carrion O
    CNS Neurol Disord Drug Targets; 2013 Dec; 12(8):1079-80. PubMed ID: 24392859
    [No Abstract]   [Full Text] [Related]  

  • 37. Common pathophysiology affecting diabetic retinopathy and Parkinson's disease.
    Tian T; Li Z; Lu H
    Med Hypotheses; 2015 Oct; 85(4):397-8. PubMed ID: 26141638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thiol Oxidation by Diamide Leads to Dopaminergic Degeneration and Parkinsonism Phenotype in Mice: A Model for Parkinson's Disease.
    Ray A; Kambali M; Ravindranath V
    Antioxid Redox Signal; 2016 Aug; 25(5):252-67. PubMed ID: 27121974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
    Porritt MJ; Batchelor PE; Howells DW
    Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adipose-derived human mesenchymal stem cells induce long-term neurogenic and anti-inflammatory effects and improve cognitive but not motor performance in a rat model of Parkinson's disease.
    Schwerk A; Altschüler J; Roch M; Gossen M; Winter C; Berg J; Kurtz A; Akyüz L; Steiner B
    Regen Med; 2015 May; 10(4):431-46. PubMed ID: 26022763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.